A Real-World Data Assessment of Pulmonary Toxicity of Inhaled Insulin for Diabetes
Main finding · COPD, emphysema or chronic bronchitis diagnosisResult — go to the resultOdds ratio 0.107 95% CI 0.014–0.787Authors' conclusion
While there are limitations to the interpretation of results from a study using RWD, it is reassuring that there was no increase in pulmonary toxicity attributable to inhaled TI for treatment of diabetes with respect to lung cancer, COPD, emphysema, and chronic bronchitis.
Study context
- Population
- Individuals with diabetes in the Epic Cosmos database, prescriptions between January 1, 2015, and October 8, 2024, >365 days between first and last prescription; excluded if increased risk of pulmonary disease before or within 1 year postindexmatched 3:1
- Participants
- 647 vs 1,830
- Exposure
- Inhaled technosphere insulin vs rapid-acting analogue insulin
- Technosphere insulin (TI)n = 647
- Rapid-acting analogue (RAA)n = 1,830reference
- Outcome
- Diagnosis codes for lung cancer, chronic obstructive pulmonary disease (COPD), emphysema and chronic bronchitis
- Follow-up
- At least 1 year after the index date
Methodological detailsreal-world data, Epic Cosmos database, controls matched 3:1
- Real-world data
- Epic Cosmos database
- Controls matched 3:1
Main finding
COPD, emphysema or chronic bronchitis diagnosis · beginning 1 year postindex date
Odds ratio
0.107
95% CI 0.014–0.787
P = 0.007
Events by group
TIvs RAA
OR 0.107 (95% CI 0.014–0.787); P = 0.007
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | TI | RAA |
|---|---|---|
| Lung cancer diagnosis · beginning 1 year postindex date | 0 events | 0.11% |
Original publication
A Real-World Data Assessment of Pulmonary Toxicity of Inhaled Insulin for Diabetes. Diabetes Technol Ther. Published 21 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →